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ABSTRACT 
Adjuvant radiotherapy after surgical treatment constitutes an indispensable part of breast-conserving therapy (BCT) 
in early breast cancer. The standard dose to the whole breast in BCT is 50 Gy delivered in 2 Gy fractions, with or 
without a boost dose to the tumour bed. A decreased risk of local recurrence, particularly in younger patients, 
as a result of a boost dose has been confirmed in a large randomised trial. Recently, mildly hypofractionated 
schedules of radiotherapy are being used more frequently in BCT. The indications and form of boost radiotherapy 
in hypofractionated schedules have not been fully determined. This article reviews randomised trials addressing 
hypofractionated radiotherapy in BCT, and particularly the role of a boost dose. We also present current recom-
mendations in these areas.
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Introduction 
Breast-conserving therapy (BCT) has been the stan-
dard of care in patients with early breast cancer since 
more than 30 years. It involves surgical tumourectomy 
together with histological evaluation of axillary lymph 
nodes and adjuvant radiotherapy to the whole breast 
with the possibility of an additional boost to the tumour 
bed. Overall survival rates of patients treated with 
either BCT or radical mastectomy are comparable, and 
the use of adjuvant radiotherapy after tumourectomy 
significantly decreases the risk of loco-regional relapse 
and death due to breast cancer [1–4]. The reduction in 
local recurrence risk by adding a boost, particularly in 
younger patients, following the whole breast irradiation 
with 50 Gy was confirmed in a large randomised trial 
[3, 4]. The standard dose of breast radiotherapy during 
BCT was 50 Gy (45–50.4 Gy) delivered in 25 frac-
tions. Recently, shortened schedules of radiotherapy to 
the whole breast have most commonly been used during 
BCT, and their efficacy is comparable with conventional 
fractionation [5–8]. Radiobiological aspects, finances, 
and patients’ convenience support the use of higher 
fraction doses.
We presented four randomised clinical trials with 
hypofractionated radiotherapy to the whole breast as 
a part of BCT published so far, as well as the role of 
boost during radiotherapy. We also presented interna-
tional and the Polish guidelines for this topic.
Randomised trials with 
hypofractionated radiotherapy  
to the whole breast 
The response to radiotherapy of normal breast tissue 
as well as breast cancer cells depends on the dose of frac-
tion and sensitivity of cells to the change of fraction dose 
is described by the a/b ratio [9]. As the a/b ratio lowers 
so the cells’ sensitivity increases with this change. It is 
currently assumed that the a/b ratio for breast cancer 
is approximately 4 Gy, and for late-responding tissues 
(skin, subcutaneous tissue, muscles, and ribs) it is slightly 
above 3 Gy [10]. Similar radiosensitivity of breast cancer 
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cells and late-responding tissues supports the possibility 
of using of higher fraction doses. 
Hypofractionated schedules of radiotherapy during 
BCT were evaluated in four previously published 
phase III randomised clinical trials: the Canadian 
Ontario Clinical Oncology Group (OCOG) [5] and 
three British studies: the Royal Marsden Hospital and 
Gloucestershire Oncology Centre (RMH/GOC) [6], 
Standardisation of Breast Radiotherapy A (START A) 
[7], and Standardisation of Breast Radiotherapy B 
(START B) [8] (Table 1). Patients enrolled to these 
trials had slightly different relapse risk factors. All four 
trials indicated comparable efficacy of hypofractionated 
and conventional radiotherapy with the dose of 50 Gy 
in terms of local and regional recurrences as well as 
cosmetic outcomes. The risk of local recurrence was 
significantly higher as compared with other schedules 
of fractionation in one arm of the RMH/GOC study 
only, when the dose of 39 Gy was used in 13 fractions 
[6]. START B showed significantly lower distant relapse 
rate and lower general morbidity in patients receiving 
hypofractionated radiotherapy (40 Gy in 15 fractions) 
compared with standard radiotherapy (7.5% and 10.5%, 
and 7.9% and 10.9%, respectively). Good and very good 
cosmetic effects were achieved by 58–74% of patients in 
individual trials, and hypofractionated schedules were 
associated with significantly lower risk of oedema and 
induration (hardness) of the breast as well as telangi-
ectasia [8]. 
It should be underlined that the majority (70–79%) 
of patients participating in the mentioned trials were 
above the age of 50 years. A stratification according to 
patients’ age was used barely in the Canadian trial that 
enrolled only 305 patients aged below 50. It was also 
Table 1. Phase III clinical trials with hypofractionated radiotherapy in breast conserving therapy (BCT) for early breast cancer
Study (ref.) OCOG [5] RMH/GOC [6] START A [7] START B [8] 
Number of patients 1234 1410 2236 2215 
Recruitment (years) 1993–1996 1986–1998 1999–2002 1999–2002
Primary/secondary 
endpoint 
Local recurrence/distant 
relapse, death, cosmetic 
effect, late toxicity
Late cosmetic 
effect/local recurrence, 
distant relapse, second 
primary cancer
Loco-regional 
recurrence, late 
cosmetic effect, quality 
of life/DFS, OS, second 
primary cancer, financial 
aspects 
Loco-regional 
recurrence, late 
cosmetic effect, quality 
of life/DFS, OS, second 
primary cancer, financial 
aspects
Staging pT1-2N0M0 pT1-3N0-1M0 pT1-3aN0-1M0 pT1-3aN0-1M0 
Age ≥ 50 years (%) 75 70 77 79 
Poorly differentiated 
cancer (G3) 
19% Not presented 28% 23% 
Follow-up after 
treatment 
10 years 9.7 years  
(median)
9.3 years
(median)
9.9 years
(median)
Radiotherapy schedules 
— study arm 
— control arm 
42.5 Gy/16 fr/22 days
50 Gy/25 fr/35 days
42.9 Gy/13 fr/35 days
39 Gy/13 fr/35 days
50 Gy/25 fr/35 days
41.6 Gy/13 fr/35 days
39 Gy/13 fr/35 days
50 Gy/25 fr/35 days
40 Gy/15 fr/21 days
50 Gy/25 fr/35 days
Proportion of patients 
with boost 
— 75% 61% 43% 
Systemic treatment 
— chemotherapy
— hormonotherapy* 
11%
41% 
14%
76% 
35%
79% 
22%
87% 
Local recurrence
— study arm
— control arm 
6.2%
6.7% 
9.6% 
14.8% 
12.1%  
3.5%
5.2%
3.6% 
2.2%
3.3% 
*Mainly tamoxifen, only a few patients received aromatase inhibitors 
OCOG — Ontario Clinical Oncology Group; RMH/GOC — Royal Marsden Hospital and Gloucestershire Oncology Centre; START — Standardisation of Breast 
Radiotherapy; DFS — disease-free survival; OS — overall survival
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the only trial including patients with no involvement of 
lymph nodes (pN0). In the remaining trials patients with 
axillary lymph nodes metastases accounted for 26–60% 
of the analysed groups. 11–35% patients enrolled to clin-
ical trials received adjuvant chemotherapy. The majority 
of patients received anthracycline-containing regimens, 
and in rare cases taxoides (25% and 13% in START A, 
and 1% and 0.4% in START B trial, respectively). None 
of the patients was treated with trastuzumab or any other 
targeted therapy. 
In the Canadian study only, a subgroup analysis con-
sidering classical clinical factors (age, tumour size, ste-
roid receptors status, histological grade, postoperative 
use of chemotherapy/hormonotherapy) demonstrated 
significantly higher risk of local recurrence in patients 
with high grade cancer (G3) receiving hypofractionated 
radiotherapy [5]. During 10 years of follow-up 15.6% of 
patients in this group experienced local recurrence com-
pared to 4.7% of patients irradiated with the use of con-
ventional fractionation [5]. In this study, patients with 
G3 tumours comprised only 19% of the entire group. 
START A and B trials, with slightly higher percentag-
es of patients with G3 tumours, did not reveal a such 
correlation. A high-grade tumour status had no impact 
on local treatment effectiveness also in the large retro-
spective study that included patients who underwent 
shortened schedules of radiotherapy during BCT [11]. 
Multivariate analysis of data from the Canadian study 
has revealed that the molecular tumour subtype is the 
only independent risk factor of local recurrence [12]. 
After a median follow-up of more than 12 years the 10-
year cumulative recurrence risk in patients with luminal 
A and basal subtype of breast cancer was 4.6%, with 
luminal B at 7.9%, and HER2-positive breast cancer at 
16.9% (p < 0.01). 
Treatment toxicity was not increased by the higher 
fraction doses, also in patients receiving chemotherapy or 
concomitant hormonotherapy with aromatase inhibitors 
[13, 14]. Hypofractionated radiotherapy in women with 
breast volume more than 1.5 L was associated with the 
lower risk of moist desquamation as compared to the 
standard radiotherapy [15]. In the Canadian study, after 
10 years of follow-up there were no differences between 
arms according to the causes of death, including cardio-
vascular. Similarly, in comparable groups in the START 
trials the incidence of ischaemic heart disease, fractures 
of ribs, and symptomatic pulmonary fibrosis were similar. 
During the St. Gallen Conference in 2013 concerned 
the treatment of early breast cancer the vast majority of 
experts agreed that shortened schedules of radiotherapy 
(40 Gy in 15 fractions or 42.5 Gy in 16 fractions) should 
be the standard of care in the majority of patients, re-
gardless of a boost to the tumour bed [16]. This opinion 
was supported during the next St. Gallen Conference 
in 2015 [17].
The role of boost in hypofractionated 
radiotherapy of breast cancer during 
BCT 
The risk of local recurrence in patients with breast 
cancer, who underwent BCT accounts for 10% after 
10 years, and continues the following years. The ma-
jority of recurrences appear in the direct surroundings 
of the tumour, and cancer cells can be found even at 
a distance of 4 cm from the primary tumour [18, 19]. 
This observation supported the increase of irradiation 
dose to the tumour bed. There are different forms of 
a boost in clinical practice [20]. The most common type 
is external beam irradiation after teletherapy to the 
whole breast. The application of intensity-modulated 
radiotherapy (IMRT) allows to deliver a boost concom-
itantly with the whole breast irradiation (so-called con-
comitant boost) [21–24]. Intra-operative administration 
of a boost directly after breast tumourectomy shortens 
total treatment time and decreases the risk of so-called 
geographical mistake during delineation of the tumour 
bed. In a retrospective analysis by the International 
Society of Intraoperative Radiation Therapy (ISIORT) 
99.2% of 1109 patients receiving intra-operative electron 
boost with the dose of 10 Gy had local control (median 
follow-up exceeded 72 months) [25]. 
The role of a boost in conventional whole breast irra-
diation was evaluated in a large clinical trial conducted 
by the European Organisation for Research and Treat-
ment of Cancer (EORTC), which enrolled 5318 pa-
tients with stage T1-2 N0-1 M0 breast cancer [3, 4]. 
Patients with axillary lymph nodes metastases account-
ed for only 20% of the entire population, and 30% of 
the patients received adjuvant systemic treatment. In 
this study patients after breast conserving surgery and 
whole-breast irradiation with 50 Gy were randomly as-
signed to receive boost with the dose of 16 Gy in eight 
fractions to the tumour bed or to be observed. In the 
majority of patients (90%) the boost was administered 
by external electron beam and the remaining patients 
were boosted with brachytherapy. The volume irradiated 
during brachytherapy included the tumour bed with the 
margin of 1.5 or 3 cm (either patients after complete 
tumourectomy or with extensive intraductal compo-
nent, respectively). The administration of the boost was 
associated with the lower rate of local recurrence after 
10 years of follow-up (6.2% vs. 10.2%, respectively) 
[3]. The greatest effect was observed in the group of 
patients under 50 years of age. Recently published long-
term results of this study showed that after a median 
follow-up of slightly more than 17 years the 20-year risk 
of local recurrence was 12% in the group of patients 
receiving boost, as compared to 16.4% in the control 
group (p < 0.0001) [4]. The benefit from the boost 
administration were noted in all age groups; however, 
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it was the greatest in the patients under 40 years of age 
and decreased with increasing age. The use of the boost 
did not influence the overall survival (59.7% and 61.1%) 
and the risk of distant relapse (26% and 24.8%), and it 
was associated with the higher risk of excessive fibrosis of 
the breast (5.2% in the group of patients receiving boost 
as compared to 1.8% in the control group; p < 0.0001). 
In the only one randomised clinical study evaluating 
the influence of a boost following shortened radiother-
apy to the breast a significant decrease in risk of local 
recurrence after boost administration was also showed, 
particularly in young patients [26]. This study included 
1024 patients with T1-2 N0-1 M0 ductal breast cancer 
with tumour size up to 3 cm, and the majority of patients 
(more than 80%) underwent lumpectomy with negative 
excision margin. The average age was 53 years, and pa-
tients at the age above 40 years accounted for 90%. In 
this study patients after irradiation to the whole breast 
with the dose of 50 Gy in 20 fractions, corresponding to 
an equivalent dose of 2 Gy per fraction (EQD2) 55 Gy 
for a/b ratio 3, were randomly assigned to the group 
receiving electron boost with the dose of 10 Gy in four 
fractions or to the group with observation alone. 23% 
and 20% of patients, respectively, had poorly differ-
entiated cancer, and adjuvant chemotherapy and hor-
monotherapy were used in 21% and 23%, and 31% and 
29% in the arm without and with the boost, respectively. 
After a median follow-up of more than three years the 
5-year risk of local recurrence in both groups was 4.5% 
and 3.6%, respectively (p < 0.044). The use of the boost 
was associated with higher risk of telangiectasia (12.4% 
and 5.9%), although the cosmetic effect in the patients’ 
assessment, was similar. The long-term results of this 
study have not been published yet. 
Among all of the clinical trials with hypofraction-
ation presented above a boost was not used only in the 
Canadian study. In the remaining trials a boost was 
used with electrons, but the percentages of patients with 
a boost varied between studies. In the RMH/GOC study 
the dose of the boost was 14 Gy in seven fractions, speci-
fied on isodose 90%. In the START studies it was 10 Gy 
in five fractions, specified on 100%. A meta-analysis of 
the factors potentially influencing treatment outcomes 
showed that the use of a boost in patients receiving hy-
pofractionated radiotherapy did not increase the toxicity 
of treatment, also in the subgroup of patients with high 
breast volume [8]. 
There are a few data published to date concerning 
the application of intra-operative boost in patients 
with shortened schedules of radiotherapy to the 
breast. In an Italian study that included 211 patients, 
the intra-opera tive electron boost in a single dose of 
12 Gy preceding teletherapy to the entire breast with 
a dose of 37.05 Gy in 13 fractions, acute toxicity grade 
1, 2, and 3 was observed in 67.6%, 28.6% and 3.8% 
of patients, respectively [27]. Grade 1–2 late toxicity 
occurred in 98.2% patients, and grade 3–4 was seen 
in two cases. The authors did not present the data 
about local recurrence. In 2011 started the HIOB 
(Hypofractionated Whole-Breast Irradiation following 
Intra-Operative Electron Boost) study in which patients 
receive intra-operative boost with electron beam in 
a single dose of 10 Gy followed by teletherapy to the 
whole breast with a dose of 40.5 Gy in 15 fractions [28]. 
After a median follow-up of 13 months there were 
neither local recurrences nor grade 3 complications.
Experts’ recommendations
According to the American Society for Radiation On-
cology (ASTRO) guidelines, the use of hypofractionated 
radiotherapy during BCT could be considered in patients 
at the age of 50 years or older, with tumour size of less 
than 5 cm, without metastases to axillary lymph nodes, 
and chemotherapy-naive [29]. The ASTRO Expert Panel 
did not agree to a common statement regarding indica-
tions for a boost in patients receiving hypofractionated 
radiotherapy to the whole breast. They stated that these 
indications are independent of the fractionation schedule 
of external irradiation to the whole breast. The Nation-
al Comprehensive Cancer Network (NCCN) experts 
recommend a boost with the dose of 10–16 Gy with 
2–2,5 Gy per fraction in the high-risk group of patients, 
e.g. at age under 50 years and with G3 tumours [30]. 
According to the British National Institute for Health 
and Care Excellence (NICE) recommendations, a boost 
following radiotherapy with the dose of 40 Gy in 15 frac-
tions is indicated in patients with increased risk of local 
relapse; however, neither the dose nor the fractionation 
schedule was defined [31]. Similarly, experts employed 
in the European Society of Medical Oncology (ESMO) 
recommend a boost in patients with unfavourable fac-
tors of local recurrence risk, e.g. age under 50 years, 
G3 tumour, extensive DCIS, vascular invasion, as well 
as positive resection margin [32]. The Polish Society 
of Clinical Oncology recommends administration of 
a boost with the dose of 10–15 Gy to the tumour bed in 
the majority of patients receiving conventional (50 Gy 
in 25 fractions) as well as hypofractionated radiotherapy 
(40 Gy in 15 fractions; EQD2 45 Gy for a/b ratio 3, which 
is currently the preferred method) [33].
Summary
Implementation of a boost to the tumour bed in 
addition to conventional radiotherapy to the whole 
breast is associated with a significant decrease of lo-
cal recurrence risk, particularly in younger patients. 
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Nevertheless, this approach does not influence overall 
survival and increases breast fibrosis. The role of boost 
in hypofractionated irradiation to the whole breast 
during BCT is not fully determined. To-date this topic 
has not been evaluated in a randomised clinical study 
with a large group of patients, with adequately long 
follow-up, and currently used schedules, in particular 
40 Gy in 15 fractions. According to experts’ opinions, 
in daily clinical practice a boost should be considered in 
patients with higher local recurrence risk, particularly 
at age below 50 years and with G3 tumours, regardless 
of the whole breast fractionation schedules.
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